Sciencast Management LP

Sciencast Management LP is a quantitatively oriented investment management firm headquartered in New York City. Founded by Jeremy Kahan, the firm operates within the systematic hedge fund space, applying scientific methodology and data-driven analytics to public equity markets. Filing with the SEC under CIK #0001653169, Sciencast Management has maintained a multi-year 13F reporting history that provides quarterly transparency into its U.S. equity allocation decisions and serves as an observable record of the outputs generated by its systematic investment framework. The firm's name — combining "science" and "forecast" — signals its foundational philosophy: that rigorous empirical analysis, statistical modeling, and predictive analytics can be applied to financial markets in ways that generate repeatable, risk-adjusted investment outcomes. This positioning places Sciencast within a specialized cohort of quantitative managers in New York who leverage computational infrastructure, alternative data, and algorithmic signal generation as their primary sources of investment edge, rather than traditional fundamental research or discretionary judgment. New York City provides the firm with access to a deep ecosystem of quantitative talent spanning data science, machine learning, financial engineering, and applied mathematics. This talent pipeline is critical for systematic firms like Sciencast, where the quality of research personnel and computational resources directly determines the sophistication and durability of the investment models that drive portfolio construction. The firm caters to institutional investors and qualified purchasers — including fund-of-funds allocators, endowments, family offices, and other sophisticated capital partners — who seek differentiated return streams uncorrelated with traditional discretionary approaches.

Sciencast Management LP employs a systematic, data-driven investment strategy that applies quantitative methods to equity selection, portfolio construction, and risk management. The firm's investment process begins with signal research — identifying statistically significant patterns in market data, corporate disclosures, alternative datasets, and other information sources — and translates those signals into portfolio positions through algorithmic execution frameworks. This end-to-end systematic approach removes discretionary bias from the investment decision chain, relying instead on empirical evidence and model outputs to determine what to own, how much to own, and when to adjust. The 13F Portfolio Composition disclosed in the firm's quarterly filings reveals a portfolio architecture that is characteristically broad in its security-level holdings. Systematic strategies typically diversify across a large number of individual positions, deploying capital in increments that reflect the strength of underlying quantitative signals rather than concentrating in a small number of high-conviction fundamental theses. This breadth-based approach is designed to aggregate many small statistical edges into a cohesive portfolio-level return stream, reducing the impact of any single position outcome on overall results while allowing the law of large numbers to work in the strategy's favor. Despite this security-level diversification, the firm's Sector Allocation History reveals meaningful concentrations in sectors that are particularly amenable to quantitative analysis. Technology, biotechnology, and healthcare innovation have featured prominently across the filing record — sectors defined by high-frequency information flow, including clinical trial results, patent activity, product development milestones, regulatory filings, and rapidly evolving competitive landscapes. These data-rich environments generate abundant inputs for quantitative modeling, and the firm's apparent sector affinity suggests that its systematic framework is optimized for processing the complex, high-volume information ecosystems that define innovation-driven industries. Turnover is high, a natural byproduct of a systematic process that continuously recalibrates portfolio positioning based on updated data signals and evolving model outputs. Unlike fundamental strategies where position changes signal a shift in investment thesis, high turnover in a systematic context reflects the ongoing optimization of a living quantitative model — positions are sized, added, reduced, and exited as the statistical landscape shifts. This active repositioning is disciplined and algorithmic rather than reactive, with each portfolio change representing the output of a defined computational process. INVESTMENT STRATEGY — QUANTITATIVE SIGNAL ARCHITECTURE The scientific backbone of Sciencast's investment process likely incorporates multiple layers of quantitative analysis. While the firm's specific model architecture is proprietary, the observable characteristics of its 13F portfolio suggest a multi-factor approach that blends different signal types — potentially including momentum indicators, mean-reversion signals, sentiment analysis derived from natural language processing of corporate communications, event-driven catalysts parsed from regulatory filings, and statistical arbitrage relationships identified through cross-sectional analysis of securities within related industry groups. The Top 10 Holdings Concentration observable through 13F filings provides a window into the conviction structure of the systematic framework. Quantitative strategies often exhibit a flatter position-sizing distribution than discretionary managers — with capital spread more evenly across many holdings rather than pyramided into a few dominant positions — though the largest positions may reflect sectors or themes where the model generates its strongest aggregate signal conviction. Tracking changes in the top holdings over time can reveal the cadence and magnitude of signal shifts that drive portfolio rebalancing. The firm's quantitative methodology also implies an integrated risk management architecture. Systematic strategies typically embed risk controls directly within the portfolio construction algorithm — including position-size limits, sector concentration bounds, correlation-aware optimization, and volatility-targeting mechanisms — rather than treating risk management as a separate, post-construction overlay. This integration ensures that risk management is not an afterthought but a structural feature of every portfolio decision.

Sciencast Management LP occupies a distinctive position within the 13F analytical landscape: a New York-based quantitative hedge fund founded by Jeremy Kahan, applying systematic, science-driven methodology to construct a dynamically managed, broadly diversified equity portfolio with observable concentration in technology, biotech, and healthcare innovation. Its multi-year filing history under CIK #0001653169 provides a substantive dataset for examining the observable behavior of its quantitative investment process across different market environments. Primary analytical dimensions include the firm's Annualized Return (CAGR) as implied through historical replication of its disclosed long-equity positions, the tempo and magnitude of portfolio restructuring across filing periods, and the Downside Capture Ratio during market stress episodes as a measure of how effectively the firm's embedded risk controls mitigate adverse capital trajectory. The high position count and elevated turnover make filing-to-filing delta analysis particularly informative, as the pattern of additions, deletions, and position-size adjustments serves as a quantitative fingerprint of the firm's evolving signal environment. The defining diagnostic question for allocators evaluating this systematic strategy centers on the durability and adaptability of quantitative edge across evolving market regimes: As the market structure, volatility regime, and macroeconomic environment undergo structural transitions — from the quantitative-friendly, low-volatility expansion of the mid-2010s through the pandemic dislocation, the subsequent speculative frenzy, and the rate-normalization regime that followed — does Sciencast Management's scientific investment framework demonstrate the capacity for continuous model evolution that sustains its predictive accuracy, or does alpha decay and signal degradation in changing regimes reveal the finite shelf life of the historical relationships that underpin its systematic compounding behavior?

The risk characteristics of Sciencast Management's disclosed portfolio reflect the inherent tension within systematic strategies between the diversification benefits of broad position-level coverage and the concentrated exposures that emerge from sector-level signal preferences. The Volatility Profile of the portfolio is shaped by this dynamic: security-level diversification across many positions reduces idiosyncratic risk, while concentrated exposure to data-rich sectors like technology and biotech introduces systematic sector risk that can amplify volatility during sector-specific dislocations. The Max Drawdown Depth experienced during market stress episodes is a critical evaluation metric for systematic strategies, as these periods often test the boundaries of the statistical relationships that underpin quantitative models. Tail-risk events — such as the March 2020 pandemic-driven liquidation, the 2022 growth-to-value rotation driven by aggressive monetary tightening, or intra-year sector corrections — can produce market behavior that deviates significantly from the historical distributions used to calibrate systematic models. The firm's drawdown behavior during these episodes reveals the robustness of its quantitative framework under conditions that may exceed its training data parameters. Model risk constitutes a distinctive category of exposure for quantitative managers. The possibility that the relationships identified by the firm's algorithms may decay, reverse, or disappear entirely — a phenomenon known as signal degradation or alpha decay — represents an ongoing challenge that requires continuous research and model evolution. Regime changes, where the macroeconomic or market-structure conditions that supported historical signals shift fundamentally, pose the most acute threat to systematic strategies. The transition from the low-rate, low-volatility environment of the 2010s to the structurally different rate landscape of 2022 onward represents precisely this type of regime shift, and the firm's ability to adapt its models through this transition is a defining test of its quantitative research capability. Execution risk is another material consideration given the strategy's high turnover. Frequent repositioning across many securities exposes the portfolio to transaction costs, market impact, and liquidity constraints that can erode theoretical alpha. During periods of market stress when spreads widen and liquidity contracts, these friction costs can increase substantially, potentially turning marginally profitable signals into net-negative positions. The Sortino Ratio provides a particularly appropriate efficiency measure for this type of strategy, as it isolates the penalty for harmful downside deviation while preserving credit for upside variance that may be an intended feature of the systematic framework. The firm's hedge fund structure affords access to short selling and derivatives that are not fully visible in 13F long-equity disclosures. The disclosed long positions may represent only one dimension of a more complex portfolio that includes offsetting shorts, pair trades, options-based hedges, or other instruments that materially alter the aggregate risk-return profile. Allocators and researchers should interpret the 13F-derived risk metrics as indicative of the long-equity component rather than the totality of the firm's risk posture.